Page 338 - ONLINE PROCEEDING BOOK WSAVA 2017
P. 338

338
An Urban Experience
Selected references
Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classi cation of pulmonary hypertension. J Am Coll Cardiol. 2009 30;54(1 Suppl):S43-54.
Borgarelli M, Abbott J, Braz-Ruivo L, et al. Prevalence and prognostic signi cance of pulmonary hypertension in dogs with myxomatous mitral valve degeneration. J Vet Intern Med 2015:29;569-574.
Kellihan HB, Stepien RL. Pulmonary hypertension in dogs: Diagnosis and therapy. Vet Clin North Am Small Anim Pract 2010;40:623–641.
Borgeat K, Sudunagunta S, Kaye B, et al. Retrospective evaluation of moderate-to-severe pulmonary hypertension in dogs naturally infected with Angiostrongylus vasorum. J Small Anim Pract 2015;56: 196-202.
Tidholm A, Höglund K, Häggström J, et aI. Diagnostic value of selected echocardiographic variables to identify pulmonary arterial hypertension in dogs with myxomatous mitral valve disease. J Vet Intern Med 2015;29:1510-1517.
Guazzi M, Arena R. Pulmonary Hypertension with left sided heart disease. Nat Rev Cardiol 2010;7:648–659.
Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219–1263.
Kellihan HB, Waller KR, Pinkos A, et al. Acute resolution of pulmonary alveolar in ltrates in 10 dogs with pulmonary hypertension treated with sildena l citrate: 2005-2014. J Vet Cardiol 2015;17(3):182-91.
42ND WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND FECAVA 23RD EUROCONGRESS


































































































   336   337   338   339   340